Drug-drug interaction mediated by inhibition and induction of P-glycoprotein

Advanced Drug Delivery Reviews

Volumn 55, Issue 1, 2003, Pages 53-81

  Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Blood brain barrier; Genetic polymorphism; P glycoprotein mediated drug interactions; Saturable efflux transport

Indexed keywords

CELLS; DRUG INFUSION; ENZYME INHIBITION; ENZYMES; PROTEINS; TOXIC MATERIALS;

BIOLOGICAL BARRIER;

DRUG INTERACTIONS;

AMPRENAVIR; ANTINEOPLASTIC AGENT; AVERMECTIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; DAUNORUBICIN; DIGOXIN; DOCETAXEL; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; INDINAVIR; IVERMECTIN; KETOCONAZOLE; LEUKOTRIENE C4; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; NIFEDIPINE; PACLITAXEL; PROTEIN INHIBITOR; QUINIDINE; RITONAVIR; SAQUINAVIR; TALINOLOL; TAUROCHOLIC ACID; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR;

BLOOD BRAIN BARRIER; BLOOD PLACENTA BARRIER; BLOOD TOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SOLUBILITY; FETOTOXICITY; GENETIC VARIABILITY; HEPATOBILIARY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REVIEW; URINARY EXCRETION; WILD TYPE;

EID: 0037457793     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00171-0     Document Type: Article

References (158)

1. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
2. Loo T.W., Clarke D.M. Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J. Biol. Chem. 269:1994;7750-7755.
3. Muller M., Bakos E., Welker E.E., Varadi A., Germann U.A., Gottesman M.M., Morse B.S., Roninson I.B., Sarkadis B. Altered drug-stimulated ATPase activity in mutants of human multidrug resistance protein. J. Biol. Chem. 271:1996;1877-1883.
4. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 87:1996;507-517.
5. Ruetz S., Gros P. Phosphatidylcholine translocase: a physiological role for the mdr 2 gene. Cell. 77:1994;1071-1081.
6. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. 84:1987;7735-7738.
7. Cordon-Cardo C., O'Brien J.P., Boccia J., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1990;1277-1287.
8. Schinkel A.H., Smit J.J.M., van Tellingen O., Beijnen J.H., Wagnaar E., Van Deemter L., Mol C.A.A.M., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., Berns A.J.M., Borst P. Disruption of the mouse mdr 1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
9. Croop J.M., Raymond M., Haber D., Devault A., Arceci R.J., Gros P., Housman D.E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue specific manner in normal mouse tissues. Mol. Cell. Biol. 9:1989;1346-1350.
10. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A.A.M., van Deemter L., Smit J.J.M., van der Valk M.A., Voordouw A.C., van Tellingen O., Zijlmans J.M.J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA. 94:1997;4028-4033.
11. Schuetz E.G., Umbenhauer D.R., Yasuda K., Brimer C., Nguyen N., Relling M.V., Schuetz J.D., Schinkel A.H. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr 1 genes. Mol. Pharmacol. 57:2000;188-197.
12. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cell layers: kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268:1993;14991-14997.
13. Hunter J., Hirst B.H., Simmons N.L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cells. Pharm. Res. 10:1993;743-749.
14. Augustijins P.F., Bradshaw T.P., Gan L.S.L., Hendren R.W., Thakker D.R. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport. Biochem. Biophys. Res. Commun. 197:1993;360-365.
15. Burton P.S., Conaradi R.A., Hilgers A.R., Ho N.F.H. Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190:1993;760-766.
16. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K.F., Borst P., Nooijen W.J., Beijen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:1997;2031-2035.
17. Mayer U., Wagnaar E., Beijnen J.H., Smit J.W., Meijer D.K.F., van Asperen J., Borst P., Schinkel A.H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol. 119:1996;1038-1044.
18. Su F.G., Huang J.D. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab. Dispos. 24:1996;142-147.
19. Gramatte T., Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. 66:1999;239-245.
20. Meerum Terwgot J.M., Malingre M.M., Beijnen J.H., ten Bokkel Huinink W.W., Rosing H., Koopman F.J., van Tellingen O., Swart M., Schellens J.H.M. Coadministration of cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5:1999;3379-3384.
21. Malingre M.M., Richel D.J., Beijinen J.H. Coadministration of cyclosporine A strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 19:2001;1160-1166.
22. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J.J., Wilkinson G.R., Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:2000;655-660.
23. Bohme M., Buchler M., Muller M., Keppler D. Differential inhibition by cyclosporines of primary-active ATP-dependent transporters in hepatocyte canalicular membrane. FEBS Lett. 333:1993;193-196.
24. Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporine A: in vitro-in vivo correlation. Br. J. Pharmacol. 118:1996;1841-1847.
25. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.-L., Turgeon K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:1997;248-260.
26. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA. 97:2000;3473-3478.
27. Creamer B. The turnover of the epithelium of small intestine. Br. Med. Bull. 23:1967;226-230.
28. Kipp H., Pichetshote N., Arias I.M. Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J. Biol. Chem. 276:2001;7218-7224.
29. Fojo A.T., Ueda K., Slamon D.J., Pollack D.G., Gottesman M.M., Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA. 84:1987;265-269.
30. Brady J.M., Cherrington N.J., Hartley D.P., Buist, N.L: S.C., Klasser C.D. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab. Dispos. 30:2002;838-844.
31. Gramatte T., Oertel R., Terhaag B., Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans. Clin. Pharmacol. Ther. 59:1996;541-549.
32. Lin J.H., Lu A.Y.H. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol. 41:2001;535-567.
33. Masuda S., Uemoto S., Hashida T., Inomata Y., Tanaka K., Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther. 68:2000;98-103.
34. Lee C.G.L., Gottesman M.M. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J. Clin. Invest. 101:1998;287-288.
35. Kim R.B., Fromm M.F., Wandel C., Leak B., Wood A.J.J., Roden D.M. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
36. Huffman D.H. Clinical use of digitalis glycosides. Am. J. Hosp. Pharm. 33:1976;179-185.
37. Kramer W.G., Reuning R.H. Use area under the curve to estimate absolute bioavailability of digoxin. J. Pharm. Sci. 67:1978;141-142.
38. Stephens R.H., O'Neill C.A., Warhurst A., Carlson L., Rowland M., Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296:2001;584-591.
39. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporine A and FK506. J. Biol. Chem. 268:1993;6077-6080.
40. Hochman J.H., Chiba M., Nishime J., Yamazaki M., Lin J.H. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P450 3A4. J. Pharmacol. Exp. Ther. 292:2000;310-318.
41. Lin J.H. Role of pharmacokinetics in the discovery and development of indinavir. Adv. Drug Deliv. Rev. 39:1999;33-49.
42. Lin J.H. Human immunodeficiency virus protease inhibitors: from drug design to clinical studies. Adv. Drug Deliv. Rev. 27:1997;215-233.
43. Wetterich U., Spahn-Langguth H., Mutschler E., Terhaag B., Rosch W., Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:1996;514-522.
44. Hebert M.F., Roberts J.P., Prueksaritanont T., Benet L.Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52:1992;453-457.
45. Handschumacher R.E. Immunosuppressive agents. Goodman Gilman A., Rall T.W., Nies A.S., Taylor P. The Pharmacological Basis of Therapeutics. 8th Edition:1990;1264-1276 McGraw-Hill, New York.
46. Mouritsen O.G., Jorgensen K., Honger T. Permeability of lipid bilayers near the phase transition. Disalvo E.A., Simon S.A. Permeability and Stability of Lipid Bilayers. 1995;137-160 CRC Press, Boca Raton, FL.
47. Pardridge W.M. Transport of protein-bound hormones into tissue in vivo. Endocr. Rev. 2:1981;103-123.
48. Rapoport S.I. Transport in cells and tissues. Rapoport S.I. Blood-Brain Barrier in Physiology and Medicine. 1976;17-42 Raven Press, New York.
49. Chikhale E.G., Ng K.-Y., Burton P.S., Borchardt R.T. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm. Res. 11:1994;412-419.
50. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:1980;682-684.
51. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37:1989;159-164.
52. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:1989;695-698.
53. Tsuji A., Terasaki T., Takabatake Y., Tenda Y., Tamai I., Yamashima T., Moritani S., Tsuruo T., Yamashita J. P-glycoprotein as the drug efflux pump in the primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1992;1427-1437.
54. Tatsuta T., Naito M., Oh-hara T., Sugawara I., Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267:1992;20383-20391.
55. Tsuji A., Tamai I., Sakata A. Restricted transport of cyclosporine A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46:1993;1096-1099.
56. Shirai A., Naito M., Tatsuta T., Dong J., Hanaoka K., Mikami K., Oh-hara T., Tsuruo T. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochem. Biophys. Acta. 1222:1994;400-404.
57. Biegel D., Spencer D.D., Pachter J.S. Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. Brain Res. 692:1995;183-189.
58. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1995;1698-1705.
59. Sugawara I., Hamada H., Tsuruo T. Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn. J. Cancer Res. 81:1990;727-730.
60. Koszdin K., Shen D.D., Bernards C.M. Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration. Anesthesiology. 1:2000;156-163.
61. Bracken M.B., Shepard M.J., Holford T.R. Administration of methylprednisolone for 24 or 48 h or tirilazad mesylate for 48 h in the treatment of acute spinal cord injury: results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. J. Am. Med. Assoc. 277:1997;1597-1604.
62. Yamazaki M., Neway W.E., Ohe T., Chen I.-W., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for P-glycoprotein mediated transport: species and predictability of in vitro results. J. Pharmacol. Exp. Ther. 296:2001;723-735.
63. Hass W., Stone J., Clough L.A. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type-1 infection. Clin. Pharmacol. Ther. 68:2000;367-374.
64. Khaliq Y., Gallicano K., Venance S. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 68:2000;637-646.
65. de Lange E.C.M., de Bock G., Schinkel A.H., de Boer A.G., Breimer D.D. BBB transport and P-glycoprotein functionality using mdr1a (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm. Res. 15:1998;1657-1665.
66. Yokogawa K., Takahashi M., Tamai I., Konishi H., Nomura M., Moritani S., Miyamoto K., Tsuji A. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm. Res. 16:1999;1213-1218.
67. Nakamura Y., Ikeda S., Furukawa T., Sumizawa T., Tani A., Akiyama S., Nagata Y. Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. 235:1997;849-853.
68. Ushigome F., Takanaga H., Matsuo H., Yanai S., Tsukimori K., Nakano H., Uchiumi T., Nakamura T., Kuwano M., Ohtani H., Sawada Y. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. 408:2000;1-10.
69. Smit J.W., Huisman M.T., van Tellingen O., Wiltshire H.R., Schinkel A.H. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 104:1999;1441-1447.
70. Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., Umbenhauer D.R. Placenta P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 12:1998;457-463.
71. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanmori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297:2001;1137-1143.
72. Krishna D.R., Klotz U. Extrahepatic metabolism of drug metabolism in humans. Clin. Pharmacokinet. 26:1994;144-160.
73. Debri K., Boobis A.R., Davis D.S., Edwards R.J. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem. Pharmacol. 50:1995;2047-2056.
74. Watkins P.B., Murray S.A., Thomas P.E., Wrighton S.A. Distribution of cytochromes P450, cytochrome b5, and NADPH-cytochrome P450 reductase in an entire human liver. Biochem. Pharmacol. 39:1990;471-476.
75. Murray G.I., Barnes T.S., Swell H.F., Ewen S.W.B., Melvin W.T., Burke M.D. The immunochemical localization and distribution of cytochrome P450 in normal hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P450. Br. J. Clin. Pharmacol. 25:1988;465-475.
76. Thummel K.E., Kunze K.L., Shen D.D. Enzyme-catalyzed process of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 27:1997;99-127.
77. Hochman J.H., Chiba M., Yamazaki M., Tang C., Lin J.H. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. J. Pharmacol. Exp. Ther. 298:2001;323-330.
78. Gan L.S., Moseley M.A., Khosla B., Augustijns P.F., Bradshaw T.P., Hendren R.W., Thakker D.R. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos. 24:1996;344-349.
79. Raeissi J.D., Hidalgo I.J., Segura-Aguilar J. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm. Res. 16:1999;625-631.
80. 3 . Mol. Pharmacol. 51:1997;741-754.
81. Lin J.H., Chiba M., Chen I.-W., Nishime J.A., deLuna F.A., Yamazaki M., Lin Y. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A and P-glycoprotein induction. Drug Metab. Dispos. 27:1999;1187-1193.
82. Lin J.H., Chiba M., Baillie T.A. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 51:1999;135-157.
83. Meijer D.K.F., Smit J.W., Muller M. Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters. Adv. Drug Deliv. Rev. 25:1997;159-200.
84. Koepsell H., Gorboulev V., Arndt P. Molecular pharmacology of organic cation transporters in kidney. J. Membr. Biol. 167:1999;103-117.
85. Kamimoto Y., Gatmaitan Z., Hsu J., Arias I.M. The function of Gp170, the multidrug-resistance gene product, in rat liver canalicular membrane vesicles. J. Biochem. Chem. 264:1989;11693-11698.
86. Watanabe T., Miyauchi S., Sawada Y., Iga T., Hanano M., Inaba M., Sugiyama Y. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver: possible roles of P-glycoprotein in biliary excretion of vincristine. J. Hepatol. 16:1992;77-88.
87. Ballet F., Vrignaud P., Robert J., Rey C., Poupon R. Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother. Pharmacol. 19:1987;240-245.
88. Kawahara M., Sakata A., Miyashita T. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci. 88:1999;1281-1287.
89. van Asperen J., van Tellingen O., Beijnen J.H. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Dispos. 28:2000;264-267.
90. Smit J.W., Schinkel A.H., Muller M., Weert B., Meijer D.K.F. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology. 27:1998;1056-1063.
91. Smit J.W., Schinkel A.H., Weert B., Meijer D.K.F. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br. J. Pharmacol. 124:1998;416-424.
92. Okamura N., Hirai M., Tanigawara Y., Tanaka K., Yasuhara M., Uesa K., Komano T., Hori R. Digoxin-cyclosporin A interaction: modulation of multidrug transporter in the kidney. J. Pharmacol. Exp. Ther. 266:1993;1614-1619.
93. 1 ). J. Pharmacol. Exp. Ther. 263:1992;840-845.
94. Horio M., Chin K.-V., Currier S.J., Goldenberg S., Willams C., Pastan I., Gottesman M.M., Handler J. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem. 264:1989;14880-14884.
95. Hori R., Okamura N., Aiba T., Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 266:1993;1620-1625.
96. De Lannoy I.A.M., Koren G., Klein J., Charuk J., Silverman M. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am. J. Physiol. 263:1992;F613-F622.
97. van Asperen J., van Tellinge O., Tijssen F., Schinkel A.H., Beijnen J.H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer. 79:1999;108-113.
98. Lin J.H., Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35:1998;361-390.
99. Ronis M.J.J., Ingelman-Sundberg M. Induction of human drug-metabolizing enzymes: mechanism and implications. Woolf T.F. Handbook of Drug Metabolism. 1999;239-262 Marcel Dekker, New York.
100. Lazarou J., Pomeraanz B.H., Corey P.N. Incidence of adverse drug interaction in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279:1998;1200-1205.
101. Duchateau A.M.J.A. Posicor: veni, vidi and foetsie. Pharm. Weekbld. 133:1998;1294-1295.
102. Ford J.M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer. 32A:1996;991-1001.
103. Tamai I., Safa A.R. Azidopine non-competitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J. Biol. Chem. 266:1991;16796-16800.
104. Ramachandra M., Ambudkar S.V., Chen D., Hrycyna C.A., Dey S., Gottesman M.M., Pastan I. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry. 37:1998;5010-5019.
105. Senior A.E., Al-Shawi M.K., Urbatsch I.L. The catalytic cycle of P-glycoprotein. FEBS Lett. 377:1995;285-289.
106. Okamura N., Hirai M., Tanigawara Y., Tanaka K., Yasuhara M., Ueda K., Komano T., Hori R. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J. Pharmacol. Exp. Ther. 266:1993;1614-1619.
107. Ayesh S., Shao Y.-M., Stein W.D. Cooperative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim. Biophys. Acta. 1316:1996;8-18.
108. Tamai I., Safa A.R. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells. J. Biol. Chem. 265:1990;16509-16513.
109. Critchfield J.W., Welsh C.J., Phang J.M., Yeh G.C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Biochem. Pharmacol. 48:1994;1437-1445.
110. Shapiro A.B., Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 250:1997;130-137.
111. Litman T., Zeuthen T., Skovsgaard T., Stein W.D. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta. 1361:1997;169-176.
112. Wandel C., Kim R.B., Kajiji S., Guenerich F.P., Wilkinson G.R., Wood A.J.J. P-glycoprotein and cytochrome P450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 59:1999;3944-3948.
113. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., Woolley J.L. Role of P-glycoprotein on CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16:1999;1206-1212.
114. Mayer U., Wagenaar E., Dorobek B., Benijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:1997;2430-2436.
115. Verschraagen M., Koks C.H.W., Schellens J.H.M., Beijnen J.H. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. 40:1999;301-306.
116. Bussey H.I. The influence of quinidine and other agents on digitalis glycosides. Am. Heart J. 104:1982;284-302.
117. Mordel A., Halkin H., Zulty L., Almog S., Zra D. Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. Clin. Pharmacol. Ther. 53:1993;457-462.
118. Pedersen K.E. Digoxin interaction: the influence of quinidine and verapamil on pharmacokinetics and receptor binding of digitalis glycosides. Acta Med. Scand. 697:(Suppl.):1985;11-40.
119. Hinderling P.H., Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther. Drug Monit. 13:1991;381-401.
120. Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Terhaag B., Ader P., Hanafy A., Langguth P. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:1998;16-24.
121. Tsuruo T., Lida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1981;1967-1972.
122. Advani R., Fisher G.A., Lum B.L., Hausdorff J., Halsey J., Litchman M., Sikic B.I. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC833), a modulator of multidrug resistance. Clin. Cancer Res. 7:2001;1221-1229.
123. Sparreboom A., St. Planting A., Jewell R.C., van der Burg M.E., van der Gaast A., der Bruijn P., Loos W.J., Nooter K., Chandler L.H., Paul E.M., Wissel P.S., Verweij J. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anti-Cancer Drugs. 10:1999;719-728.
124. Minami H., Ohtsu T., Fujii H., Igarashi T., Itoh K., Uchiyama-Kokubu N., Aizawa T., Watanabe T., Uda Y., Tanigawara Y., Sasaki Y. Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. Jpn. J. Cancer Res. 92:2001;220-230.
125. Giaccone G., Linn S.C., Welink J., Catimel G., Stieltjes H., van der Vijgh W.J., Eeltink C., Vermorken J.B., Pinedo H.M. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 3:1997;2005-2015.
126. Malingre M.M., Beijnen J.H., Rosing H. Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer. 84:2001;42-47.
127. Fracasso P.M., Westerveldt P., Fears C.A. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar) refractory malignancies. J. Clin. Oncol. 18:2000;1124-1134.
128. Boote D.J., Dennis I.F., Twentyman P.R. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14:1996;610-618.
129. van Zuylen L., Nooter K., Sparreboom A., Verweij J. Development of multidrug resistance converters: sense or nonsense? Invest. New Drugs. 18:2000;205-220.
130. Fardel O., Lecureur V., Corlu A., Guillouzo A. P-Glycoprotein induction in rat liver epithelial cells in response to acute 3-methycholanthrene treatment. Biochem. Pharmacol. 51:1996;1427-1436.
131. Chin K.-V., Chauhan S.S., Pastan I., Gottesman M.M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1:1990;361-365.
132. LeCluyse E.L. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem. Biol. Interact. 134:2001;283-289.
133. Fardel O., Lecureur V., Guillouzo A. Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett. 327:1993;189-193.
134. Zhao J.Y., Ikeguchi M., Eckersberg T., Kuo T. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology. 133:1993;521-528.
135. Salphati L., Benet L.Z. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem. Pharmacol. 55:1998;387-395.
136. Liu J., Brunner L.J. Chronic cyclosporine administration induces renal P-glycoprotein in rats. Eur. J. Pharmacol. 418:2001;127-132.
137. Jette L., Beaulieu E., Leclerc J.-M., Beliveau R. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol. 270:1996;F756-F765.
138. Lee C.H. Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated. Mol. Cell. Biochem. 216:2001;103-110.
139. Durr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., Fattinger K. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:2000;598-604.
140. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P450 3A coordinately up-regulated these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:1996;311-318.
141. Pichard L., Fabre I., Daujat M., Domergue J., Joyeux H., Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultured human hepatocytes. Mol. Pharmacol. 41:1992;1047-1055.
142. Wacher V.J., Wu C.-Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:1995;129-134.
143. Callen D.F., Baker E., Simmers R.N., Roninson I.B. Localization of the human multidrug resistance gene, MDR1, to 7q21.1. Hum. Genet. 77:1987;142-144.
144. Inoue K., Inazawa J., Nakagawa H., Shimada T., Yamazaki H., Guenerich F.P., Abe T. Assignment of the human cytochrome P450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. Jpn. J. Hum. Genet. 37:1992;133-138.
145. Quattrochi L.C., Guzelian P.S. CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab. Dispos. 29:2001;615-622.
146. Jones S.A., Moore L.B., Shenk J.L., Wisely G.B., Hamilton G.A., Mckee D.D., Tomkinson N.C.O., LeCluyse E.L., Lambert M.H., Wilson T.M., Kliewer S.A., Moore J.T. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:2000;27-39.
147. Blumberg B., Sabbagh W. Jr., Juguilon H., Bolado J. Jr., van Meter C.M., Ong E.S., Evans R.M. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:1998;3195-3205.
148. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Wilson T.M., Collins J.L., Kliewer S.A. St. John's Wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA. 97:2000;7500-7502.
149. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7:2001;584-590.
150. Geick A., Eichelbaum M., Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:2001;14581-14587.
151. Masuyama H., Hiramatsu Y., Mizutani Y., Inoshita H., Kudo T. The expression of pregnane X receptor and its target gene, cytochrome P450 3A1 in prenatal mouse. Mol. Cell. Endocrinol. 172:2001;47-56.
152. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.-P., von Richter O., Zundler J., Kroemer H. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:1999;147-153.
153. Westphal K., Weinbrenner A., Zschiesche M., Oertel R., Terhaag B., Kroemer H., Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68:2000;345-355.
154. Hamman M.A., Bruce M.A., Haehner-Daniels B.D., Hall S.D. The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. 69:2001;114-121.
155. Lippert C., Ling J., Brown P., Burmaster S., Eller M., Cheng L., Thompson R., Weir S. Mass balance and pharmacokinetics of MDL16,455A in healthy male volunteers. Pharm. Res. 12:1999;S390. abstract.
156. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:1999;866-871.
157. Wacher V.J., Silverman J.A., Zhang Y., Benet L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87:1998;1322-1330.
158. Makhey V.D., Guo A., Norris D.A., Hu P., Yan J., Sinko P.J. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res. 15:1998;1160-1167.